Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Bevacizumab Shows Significant Single-Agent Activity in Ovarian Cancer
Link ID 1278
Title Bevacizumab Shows Significant Single-Agent Activity in Ovarian Cancer
Url http://www.medscape.com/viewarticle/566643?src=rss
Description Bevacizumab has shown significant single-agent activity in relapsed ovarian cancer in 2 phase 2 trials, prompting further studies of this disease. Medscape Medical News
Category Articles > Hematology-Oncology
Keywords
Date Dec 4, 2007
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Hematology-Oncology
1. Toremifene Reduces Fractures and Hot Flashes From ADT in Prostate Cancer
  Toremifene reduces hot flashes and vertebral fractures in men with prostate cancer on androgen-deprivation therapy for prostate cancer. Medscape Medical News
Category:   Articles > Hematology-Oncology


2. Gene Overexpressed in Prostate Cancers Now Linked to Diffuse-Type Gastric Cancers
  A genome-wide association study in Japanese populations finds that PSCA is a susceptibility gene for diffuse-type gastric adenocarcinomas. Medscape Medical News
Category:   Articles > Hematology-Oncology


3. Treatment of Metastatic Melanoma: Current and Emerging Strategies
  In this audio program, experts detail the few currently available treatments for patients with metastatic melanoma and highlight new data emerging from trials of 3 promising new therapies. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology


4. Prostate Cancer Genomics: A Rational Roadmap Through the Maze?
  Dr. Bradley A. Patay discusses several important papers reporting on the relationships of multiple genetic markers to prostate cancer.
Medscape Pathology
Category:   Articles > Hematology-Oncology


5. Individualizing Therapy for Renal Cell Carcinoma: Rationale, Clinical Considerations, and Challenges
  In this expert interview, Dr. Gary Hudes addresses prognostication and individualization of targeted and other therapies for patients with renal cell carcinoma as well as management of known and emerging toxicities. Medscape Hematology-Oncology
Category:   Articles > Hematology-Oncology




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS